Sebastian Gallina

关于

暂无简介。

研究焦点

主要成就

代表论文

1. 1
   Advanced age portends poorer prognosis after radical prostatectomy: a single center experience

   30 次引用 · 2022
2. 2
   Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection

   21 次引用 · 2020
3. 3
   Postoperative outcomes of transperitoneal versus retroperitoneal robotic partial nephrectomy: a propensity-score matched comparison focused on patient mobilization, return to bowel function, and pain

   14 次引用 · 2024
4. 4
   Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center

   13 次引用 · 2021
5. 5
   American Society of Anesthesiologists (ASA) physical status system predicts the risk of postoperative Clavien–Dindo complications greater than one at 90 days after robot-assisted radical prostatectomy: final results of a tertiary referral center

   13 次引用 · 2022
6. 6
   American Society of Anesthesiologists’ (ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer Patients

   9 次引用 · 2022
7. 7
   High-volume surgeons decrease operating time in robot-assisted radical prostatectomy: results in 1229 patients

   6 次引用 · 2024
8. 8
   Advanced age is an independent prognostic factor of disease progression in high-risk prostate cancer: results in 180 patients treated with robot-assisted radical prostatectomy and extended pelvic lymph node dissection in a tertiary referral center

   5 次引用 · 2023
9. 9
   Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?

   4 次引用 · 2024
10. 10
    The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b

    4 次引用 · 2024

主要合作者